Figure 4.
AML cells exposed to an ANXA5-deficient BMM show increased blasts and DNA damage. (A) Representative immunofluorescence images (left) and quantification (right) of bone sections from WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML (retroviral transduction/transplantation model), stained for PGE2 (red) and DAPI (blue), on day 40 after transplantation (P = .038; t test; n = 4-5). The scale bar represents 40 μm. Four different fields from 4 individual mice were imaged; each dot represents the average per mouse. (B) Percentage of cells positive for phagocytosed, phycoerythrin-conjugated pHrodo Escherichia coli bioparticles of GFP (MLL-AF9)+ Gr1+ cells. The AML cells were taken from the BM of WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML on day 40 after transplantation (P = .024; n = 12-13). (C) Representative images of Giemsa-stained cytospins of BM cells from WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML (left) on day 40 after transplantation and quantification of the respective percentage of blasts of total leukocytes (right) (P = .023; t test; n = 4-5). The scale bar represents 25 μm. Four different fields from 4 to 5 individual mice were imaged; each dot represents the average per mouse. (D) Percentage of cells in the G0, G1, and G2/S phases of the cell cycle of GFP (MLL-AF9)+ Lin– cells. Cells were derived from the BM of WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML on day 40 after transplantation (P = .039; P = .021; 2-way ANOVA; Tukey test; n = 9-10). (E) Median fluorescence intensity (MFI) of γH2A.X in GFP (MLL-AF9)+ Lin– cells in the BM (left) or spleen (right) of WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML on day 40 after transplantation (P = .035; t test; n = 6-7). (F) Representative immunofluorescence images of nuclear β-catenin levels of GFP (MLL-AF9)+ Lin– cells sorted from the BM of WT or ANXA5 KO recipient mice with MLL-AF9–induced AML, stained for β-catenin (green) and DAPI (blue) on day 40 after transplantation (n = 4). The scale bar represents 25 μm. Four different fields from 4 individual mice were imaged; each dot represents the average per mouse. (G) Schematic representation of the proposed interaction between AML cells and cells of the BMM. AML cell–derived TNF-α stimulates increased production of PGE2 by cells of the BMM. PGE2 leads to increased expression of β-catenin and HIF-1α via its binding to the prostaglandin E receptor 4. (H) Correlation of the messenger RNA (mRNA) levels of TNF and CTNNB1 (β-catenin) in patients with AML. (I) Correlation of the mRNA levels of PTGER4 and HIF1A (HIF-1α) in patients with AML. (J) Correlation of the mRNA levels of TNF and HIF1A (HIF-1α) in patients with AML. The correlation analyses were performed using the data from the Oregon Health and Science University study by Verma et al,29 which was accessed via the cBioPortal. EP4, prostaglandin E2 receptor EP4; RNA seq, RNA sequencing; RPKM, reads per kilobase of transcript per million mapped reads.

AML cells exposed to an ANXA5-deficient BMM show increased blasts and DNA damage. (A) Representative immunofluorescence images (left) and quantification (right) of bone sections from WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML (retroviral transduction/transplantation model), stained for PGE2 (red) and DAPI (blue), on day 40 after transplantation (P = .038; t test; n = 4-5). The scale bar represents 40 μm. Four different fields from 4 individual mice were imaged; each dot represents the average per mouse. (B) Percentage of cells positive for phagocytosed, phycoerythrin-conjugated pHrodo Escherichia coli bioparticles of GFP (MLL-AF9)+ Gr1+ cells. The AML cells were taken from the BM of WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML on day 40 after transplantation (P = .024; n = 12-13). (C) Representative images of Giemsa-stained cytospins of BM cells from WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML (left) on day 40 after transplantation and quantification of the respective percentage of blasts of total leukocytes (right) (P = .023; t test; n = 4-5). The scale bar represents 25 μm. Four different fields from 4 to 5 individual mice were imaged; each dot represents the average per mouse. (D) Percentage of cells in the G0, G1, and G2/S phases of the cell cycle of GFP (MLL-AF9)+ Lin cells. Cells were derived from the BM of WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML on day 40 after transplantation (P = .039; P = .021; 2-way ANOVA; Tukey test; n = 9-10). (E) Median fluorescence intensity (MFI) of γH2A.X in GFP (MLL-AF9)+ Lin cells in the BM (left) or spleen (right) of WT (red) or ANXA5 KO (blue) recipient mice with MLL-AF9–induced AML on day 40 after transplantation (P = .035; t test; n = 6-7). (F) Representative immunofluorescence images of nuclear β-catenin levels of GFP (MLL-AF9)+ Lin cells sorted from the BM of WT or ANXA5 KO recipient mice with MLL-AF9–induced AML, stained for β-catenin (green) and DAPI (blue) on day 40 after transplantation (n = 4). The scale bar represents 25 μm. Four different fields from 4 individual mice were imaged; each dot represents the average per mouse. (G) Schematic representation of the proposed interaction between AML cells and cells of the BMM. AML cell–derived TNF-α stimulates increased production of PGE2 by cells of the BMM. PGE2 leads to increased expression of β-catenin and HIF-1α via its binding to the prostaglandin E receptor 4. (H) Correlation of the messenger RNA (mRNA) levels of TNF and CTNNB1 (β-catenin) in patients with AML. (I) Correlation of the mRNA levels of PTGER4 and HIF1A (HIF-1α) in patients with AML. (J) Correlation of the mRNA levels of TNF and HIF1A (HIF-1α) in patients with AML. The correlation analyses were performed using the data from the Oregon Health and Science University study by Verma et al,29 which was accessed via the cBioPortal. EP4, prostaglandin E2 receptor EP4; RNA seq, RNA sequencing; RPKM, reads per kilobase of transcript per million mapped reads.

Close Modal

or Create an Account

Close Modal
Close Modal